#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that older adults are increasingly using cannabis for symptom management, yet this population lacks robust safety data on dosing, drug interactions, and long-term effects at the levels they’re consuming. The growing market of older cannabis users highlights a critical gap between dispensary recommendations and evidence-based medical guidance, requiring physicians to develop competency in cannabis counseling to prevent adverse events and medication interactions in their aging patients.
# Summary The increasing population of older cannabis users represents a significant clinical challenge that clinicians must address proactively. While dispensaries benefit commercially from this demographic shift, physicians face growing concerns about appropriate dosing, drug interactions, and safety monitoring in elderly patients who may be taking multiple medications and have age-related physiological changes affecting cannabis metabolism. The article highlights that older patients are self-titrating to relatively high daily doses (40-50 mg) without robust clinical guidance, raising questions about efficacy, adverse effects, and long-term outcomes in this vulnerable population. Medical marijuana card programs have expanded access for seniors, but the clinical infrastructure to safely counsel older adults on cannabis use remains underdeveloped compared to conventional pharmaceutical management. Physicians encountering older cannabis users should establish clear documentation of indications, baseline function, and dosing strategies while considering potential interactions with other medications and monitoring for cognitive, cardiovascular, and fall-related harms. Clinicians should engage routinely with patients about their cannabis use and develop evidence-based dosing protocols tailored to older adults rather than allowing patients to navigate dispensary recommendations without medical oversight.
“What we’re seeing with older adults is that many are self-titrating to doses that would be considered high by any standard, and without baseline cognitive or fall-risk assessments before they start, we’re essentially flying blind on safety in a population where the consequences of impaired balance or memory are genuinely serious.”
💊 The rising prevalence of cannabis use among older adults presents a significant clinical challenge that warrants careful attention in primary care and geriatric medicine. While aging patients may perceive cannabis as a safer alternative to opioids or other medications for chronic pain, anxiety, or sleep disturbance, the dosing patterns described in this article (40-50 mg daily) substantially exceed conservative prescribing guidelines and raise concerns about drug interactions, cognitive effects, and fall risk in a population already vulnerable to adverse events. Clinicians should recognize that older adults often have altered pharmacokinetics, polypharmacy concerns, and limited evidence regarding long-term safety of regular cannabis use in this age group, yet patients may not disclose cannabis consumption unless directly asked. Rather than dismissing cannabis use, healthcare providers should adopt a harm-reduction approach by routinely asking about cannabis consumption, discussing appropriate dosing and administration routes, screening for drug interactions, and monitoring for cognitive
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: